Delix Therapeutics said early clinical data for its non‑hallucinogenic neuroplastogen showed promise in depression, and the FDA cleared the company to permit at‑home dosing in its upcoming Phase 2 study. Regulators’ acceptance of at‑home administration for a psychedelic‑adjacent molecule represents a first for the class and removes a key logistical barrier that has made psychedelic‑assisted trials clinic‑bound and expensive. Delix described the study design changes as enabling broader recruitment and lower site burden; the company stressed the compound lacks hallucinatory effects and therefore merits different monitoring than classic psychedelics. The decision may set a precedent for other next‑generation neuroplasticity agents and influence how regulators balance risk, monitoring and accessibility for psychiatric drug trials.